4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-014915
PRESIDENT AND CEO sold 12,000 shares at an average $23.18 ($278,210)
- PRESIDENT AND CEO acquired 12,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Kintz Samuel · PRESIDENT AND CEO
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-05-28 | Exercise or conversion : show line 1 in the form 10b5-1 | +12,000 | $1.12 | $13,440 | 12,000 | D |
| 2024-05-28 | Sale : show line 2 in the form 10b5-1 | −6,681 | $22.86 | $152,756 | 5,319 | D |
| 2024-05-28 | Sale : show line 3 in the form 10b5-1 | −5,219 | $23.57 | $123,020 | 100 | D |
| 2024-05-28 | Sale : show line 4 in the form 10b5-1 | −100 | $24.34 | $2,434 | 0 | D |
| Open-market sales · 12,000 sh · avg $23.18 · $278,210 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2024-05-28 | Exercise or conversion : show line 5 in the form 10b5-1 Stock Option (right to buy) | −12,000 | 188,841 | D |
Loading xslF345X05/form4-05302024_090556.xml…